Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.

Jiang W, Li W, Cheng J, Li W, Cheng F

Sleep & breathing = Schlaf & Atmung21 Dec 2022Cited by 61 (Europe PMC)

PMID36542275PMCIDPMC10539428DOI10.1007/s11325-022-02768-yPepBankPUB-36542275

Summary

ObjectivesTo observe the efficacy and side effects of liraglutide in the treatment of type 2 diabetes mellitus (T2DM) patients with severe obstructive sleep apnea (OSA).MethodsThe study conducted in an outpatient setting was a two-center, prospective randomized controlled study. T2DM patients with severe OSA were randomized to the control group (continuous positive airway pressure [CPAP] and drug treatment without liraglutide) or the liraglutide group (CPAP and drug treatment including liraglutide). Demographic and clinical characteristics, sleep-disordered breathing indices, cardiac function indices, and side effects were evaluated and compared between the two groups before and after 3 months.ResultsOf 90 patients, 45 were randomized to the intervention arm (with liraglutide) and 45 to the control arm (without liraglutide). One patient in the liraglutide group dropped out of the study on day 8 after enrollment due to obvious gastrointestinal symptoms. No significant differences were found between the two groups in baseline demographics, clinical characteristics, cardiac function indicators, or sleep disorder respiratory indices (P > 0.05). After 3 months, the body mass index (BMI), apnea hypopnea index (AHI), and mean systolic blood pressure in the liraglutide treatment group were significantly lower than those in the control group (P < 0.05). The minimum oxygen saturation was significantly higher in the liraglutide group compared with that in the control group after 3 months of follow-up (P < 0.05). No difference was found between the two groups in the summary of side effects (P > 0.05).ConclusionsLiraglutide combined with CPAP can effectively reduce BMI, lower mean systolic blood pressure, and improve AHI scores and hypoxia in T2DM patients with severe OSA. Liraglutide did not increase side effects.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and severe obstructive sleep apnea, BMI was significantly lower with liraglutide plus CPAP than with the control arm after 3 months.
In plain wordsIn adults with type 2 diabetes and severe sleep apnea, liraglutide plus CPAP gave a lower BMI than CPAP and usual drugs alone.
Peptide
Liraglutide
Outcome
DecreaseBody mass index at 3 months
Study
n = 90
Comparator
CPAP and drug treatment without liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3 months, the body mass index (BMI), apnea hypopnea index (AHI), and mean systolic blood pressure in the liraglutide treatment group were significantly lower than those in the control group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with severe OSA were randomized to the control group (continuous positive airway pressure [CPAP] and drug treatment without liraglutide) or the liraglutide group (CPAP and drug treatment including liraglutide).
Show in the study text Report a problemFND-3654227501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and severe obstructive sleep apnea, the apnea hypopnea index was significantly lower with liraglutide plus CPAP than with the control arm after 3 months.
In plain wordsIn adults with type 2 diabetes and severe sleep apnea, liraglutide plus CPAP gave fewer breathing pauses than CPAP and usual drugs alone.
Peptide
Liraglutide
Outcome
DecreaseApnea hypopnea index at 3 months
Study
n = 90
Comparator
CPAP and drug treatment without liraglutide
Outcome group
Sleep · Respiratory
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3 months, the body mass index (BMI), apnea hypopnea index (AHI), and mean systolic blood pressure in the liraglutide treatment group were significantly lower than those in the control group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with severe OSA were randomized to the control group (continuous positive airway pressure [CPAP] and drug treatment without liraglutide) or the liraglutide group (CPAP and drug treatment including liraglutide).
Show in the study text Report a problemFND-3654227502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and severe obstructive sleep apnea, mean systolic blood pressure was significantly lower with liraglutide plus CPAP than with the control arm after 3 months.
In plain wordsIn adults with type 2 diabetes and severe sleep apnea, liraglutide plus CPAP gave lower systolic blood pressure than CPAP and usual drugs alone.
Peptide
Liraglutide
Outcome
DecreaseMean systolic blood pressure at 3 months
Study
n = 90
Comparator
CPAP and drug treatment without liraglutide
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3 months, the body mass index (BMI), apnea hypopnea index (AHI), and mean systolic blood pressure in the liraglutide treatment group were significantly lower than those in the control group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with severe OSA were randomized to the control group (continuous positive airway pressure [CPAP] and drug treatment without liraglutide) or the liraglutide group (CPAP and drug treatment including liraglutide).
Show in the study text Report a problemFND-3654227503
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and severe obstructive sleep apnea, minimum oxygen saturation was significantly higher with liraglutide plus CPAP than with the control arm after 3 months.
In plain wordsIn adults with type 2 diabetes and severe sleep apnea, liraglutide plus CPAP gave higher lowest oxygen levels than CPAP and usual drugs alone.
Peptide
Liraglutide
Outcome
IncreaseMinimum oxygen saturation at 3 months
Study
n = 90
Comparator
CPAP and drug treatment without liraglutide
Outcome group
Sleep · Respiratory
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The minimum oxygen saturation was significantly higher in the liraglutide group compared with that in the control group after 3 months of follow-up (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with severe OSA were randomized to the control group (continuous positive airway pressure [CPAP] and drug treatment without liraglutide) or the liraglutide group (CPAP and drug treatment including liraglutide).
Show in the study text Report a problemFND-3654227504
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and severe obstructive sleep apnea, side effects did not differ between the liraglutide and control arms.
In plain wordsIn adults with type 2 diabetes and severe sleep apnea, side effects were not different with liraglutide than without it.
Peptide
Liraglutide
Outcome
No significant changeSummary of side effects
Study
n = 90
Comparator
CPAP and drug treatment without liraglutide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
No difference was found between the two groups in the summary of side effects (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with severe OSA were randomized to the control group (continuous positive airway pressure [CPAP] and drug treatment without liraglutide) or the liraglutide group (CPAP and drug treatment including liraglutide).
Show in the study text Report a problemFND-3654227505
06HumanRandomized controlled trialSafety outcome
In the liraglutide arm, one patient dropped out on day 8 because of obvious gastrointestinal symptoms.
In plain wordsIn the liraglutide arm, one patient left the study on day 8 because of stomach and gut symptoms.
Peptide
Liraglutide
Outcome
Not applicableDropout due to gastrointestinal symptoms
Study
n = 45
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
One patient in the liraglutide group dropped out of the study on day 8 after enrollment due to obvious gastrointestinal symptoms.
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with severe OSA were randomized to the control group (continuous positive airway pressure [CPAP] and drug treatment without liraglutide) or the liraglutide group (CPAP and drug treatment including liraglutide).
Show in the study text Report a problemFND-3654227506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.